NASH is a major target of drug development, yet the most severe and deadly stage of this – decompensated liver – is being virtually ignored

NASH is a multi-modal disease. Bast takes the approach of attacking all modalities while working to minimize the often-disastrous side effects that come with treatment

While initially targeting the unmet needs disease of decompensated liver, Bastet 101’s mechanism of action has potential in the larger NASH space and in other fibrotic diseases